News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25
Marwan Fakih/X
Jan 28, 2025, 17:23

Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25

Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared a post on X:

“Today, at GI ASCO, I had the privilege of presenting the results of R Phase 2 study of BOT +/- BAL in chemoresistant MSS CRC – an area in dire need of treatment options. BOT75/BAL240 ORR 19%, DCR 55%. BAL value confirmed. Majority study responses ongoing. Durable responses matter.”

Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25

More posts featuring Marwan Fakih.

ASCO GI 25 cancer colorectal cancer Marwan Fakih MSS CRC OncoDaily Oncology
Special Coverage
Science
Apr 2, 2025, 11:04
Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial
Science
Apr 2, 2025, 10:53
Diego A. Díaz García: Cross-priming is key in cancer immunotherapy
Science
Apr 2, 2025, 10:29
Bishal Gyawali: Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers
Blog
Apr 2, 2025, 10:15
IMF Regional Community Workshop to learn all about MM - International Myeloma Foundation
Blog
Apr 2, 2025, 10:10
Ready to coordinate Advisory Board in Basilicata to improve oncology research - Sbarro Health Research Organization
Blog
Apr 2, 2025, 10:07
Teresa Amaral: Discussing neoadjuvant therapy in skin cancer at the 27th International Dermatology Meeting
Blog
Apr 2, 2025, 10:05
Wafaa M Rashed: Personalized HIV Treatment in Africa
Career
Apr 2, 2025, 10:01
Karen Knudsen: I’ve taken the helm of Parker Institute for Cancer Immunotherapy (PICI) as CEO
Blog
Apr 2, 2025, 09:58
John F. Kurland presented about immuno-oncology therapies at the IO360 Summit
Blog
Apr 2, 2025, 09:54
ACC 2025 Clinical Trials to Watch with Deepak Bhatt - Mount Sinai Department of Medicine
Blog
Apr 2, 2025, 09:46
Orouba Almilaji: NATCAN - improving the quality of National Health Service cancer care in England and Wales
Blog
Apr 2, 2025, 09:45
Susanna Fletcher Greer: The V Foundation grantee Stefani Thomas and her team explored PDX models in ovarian cancer